CD8A and melanoma: Huang et al. recently reported that nivolumab in combination with stattic enhances the efficacy and immune response of anti-PD-1 in the immunocompetence for melanoma cells xenograft model through boosting the expression of TIM-3 in CD8+ T cells and decreasing the immune-suppressive cytokines IL-10 and TGF-β production in Treg cells [293].